Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIALNola M. Hylton, Mitchell D. Schnall, Jeffrey D. Blume et al.|Radiology|2012Cited by 487
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood FlowJames Stevenson, Peter J. O’Dwyer, Mark Rosen et al.|Journal of Clinical Oncology|2003Cited by 293
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIALNola M. Hylton, Mark Rosen, Constance D. Lehman et al.|Radiology|2015Cited by 276
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationMax M. Wattenberg, Kim A. Reiss, Daniella Asch et al.|British Journal of Cancer|2019Cited by 206
Phase I Trial of Combretastatin A-4 Phosphate with CarboplatinJoshua H. Bilenker, Peter J. O’Dwyer, Keith T. Flaherty et al.|Clinical Cancer Research|2005Cited by 99